Josh Welsh

Josh Welsh

Josh Welsh is a senior journalist in the Wealth vertical for Key Media, where he covers the people, firms, and trends in the benefits and pensions space. As lead reporter for Benefits and Pensions Monitor (BPM), he reports on institutional investing, pension governance, retirement policy, as well as employer-sponsored benefits plans. He has also contributed to BPM's sister US publication InvestmentNews.

His reporting draws on direct conversations with industry experts, CIOs, plan sponsors and portfolio managers, translating complex developments in capital markets, pension plans and regulation into clear, accurate coverage for industry decision-makers. He adheres to Key Media's editorial standards on sourcing, verification, and disclosure, and is committed to accuracy, balance, and accountability to readers.

Josh is a Humber Polytechnic graduate, with a bachelor's in journalism and a diploma in screen acting. Outside the newsroom, he's a member of the historic Arts and Letters Club of Toronto, an avid filmgoer, and continues to pursue his passion for acting.

Email | LinkedIn 

Could a defined benefit pension be your new retention strategy?

Abacus CEO explains why young Canadians value DB pensions more than homeownership

Could a defined benefit pension be your new retention strategy?

Monthly Spotlight: Consultants

Read BPM's highlighted coverage of key topics from June

Monthly Spotlight: Consultants

What CUSMA's ‘uncertain’ path means for Canadian plan sponsors

Markets may be underpricing CUSMA risk for institutional investors, experts warn

What CUSMA's ‘uncertain’ path means for Canadian plan sponsors

Stigma blocks young men from using benefits support: GreenShield

GreenShield’s Dr. Khush Amaria explains why young men disengage from mental health care, where benefits stand, and what plan sponsors can do

Stigma blocks young men from using benefits support: GreenShield

Generic GLP-1s are here at $125 but brand names take priority

Medical director at Phoenix and Raven explains why brand-name Ozempic still leads despite Health Canada approvals

Generic GLP-1s are here at $125 but brand names take priority

Health Canada approves first generic semaglutide for weight loss

The authorization could ease cost pressures on group benefit plan sponsors covering GLP-1 drugs

Health Canada approves first generic semaglutide for weight loss

What the SpaceX IPO means for Maple Eight pension strategy

Experts weigh in on what SpaceX reveals about the private market gap for pensions

What the SpaceX IPO means for Maple Eight pension strategy

Maple Eight pension manager posts 6.7 per cent return

Gross assets under management for the BC-based pension fund grew to $313.7 billion from $295 billion the prior year

Maple Eight pension manager posts 6.7 per cent return

New realities shape Canadian drug benefit plans: Barbara Martinez

Canada Life’s national practice leader highlights what’s next for Canadian plan sustainability

New realities shape Canadian drug benefit plans: Barbara Martinez

Canadian benefit plans fall short on 2SLGBTQI inclusion: experts

Normandin Beaudry, GreenShield make the business case for inclusive benefit plans

Canadian benefit plans fall short on 2SLGBTQI inclusion: experts